And obviously as we're going to get into much more than just obesity and obesity related conditions
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
It typically begins within the first one to three days after an injection, peaks during the first week, and gradually diminishes over the next two to four weeks as your body adjusts to the medication
Emphasize lifestyle interventions (nutrition, exercise) to sustain metabolic gains following drug cessation, minimizing rebound weight gain and reproductive fluctuations
doi: 10.3389/fendo.2021.721198 23 CalsolaroVEdisonP
Researchers use them after they have been stably transfected to express the human GIP receptor, the human GLP-1 receptor, or both